Concise Review: Process Development Considerations for Cell Therapy

被引:102
作者
Campbell, Andrew [1 ,2 ]
Brieva, Thomas [1 ,3 ]
Raviv, Lior [1 ,4 ]
Rowley, Jon [1 ,5 ]
Niss, Knut [1 ,6 ]
Brandwein, Harvey [1 ,7 ]
Oh, Steve [1 ,8 ]
Karnieli, Ohad [1 ,4 ]
机构
[1] Int Soc Cellular Therapy Proc & Product Dev Subco, Vancouver, BC, Canada
[2] Thermo Fisher Sci, Grand Isl, NY 14072 USA
[3] Celgene Cellular Therapeut, Warren, NJ USA
[4] Pluristem Therapeut Inc, Haifa, Israel
[5] Rooster Bio Inc, Frederick, MD USA
[6] Novartis Pharmaceut, Morris Plains, NJ USA
[7] Pall Life Sci, Port Washington, NY USA
[8] ASTAR, Bioproc Technol Inst, Stem Cell Grp, Singapore, Singapore
关键词
Process development; Mesenchymal stem cells; Cellular therapy; T cell; Pluripotent stem cells; PLURIPOTENT STEM-CELLS; OSTEOGENIC DIFFERENTIATION; HIGH-DENSITY; EXPANSION; CULTURE; DESIGN;
D O I
10.5966/sctm.2014-0294
中图分类号
Q813 [细胞工程];
学科分类号
摘要
The development of robust and well-characterized methods of production of cell therapies has become increasingly important as therapies advance through clinical trials toward approval. A successful cell therapy will be a consistent, safe, and effective cell product, regardless of the cell type or application. Process development strategies can be developed to gain efficiency while maintaining or improving safety and quality profiles. This review presents an introduction to the process development challenges of cell therapies and describes some of the tools available to address production issues. This article will provide a summary of what should be considered to efficiently advance a cellular therapy from the research stage through clinical trials and finally toward commercialization. The identification of the basic questions that affect process development is summarized in the target product profile, and considerations for process optimization are discussed. The goal is to identify potential manufacturing concerns early in the process so they may be addressed effectively and thus increase the probability that a therapy will be successful. STEM CELLS TRANSLATIONAL MEDICINE 2015;4:1155-1163
引用
收藏
页码:1155 / 1163
页数:9
相关论文
共 21 条
[1]  
Bardy J, 2013, TISSUE ENG PART C-ME, V19, P166, DOI [10.1089/ten.tec.2012.0146, 10.1089/ten.TEC.2012.0146]
[2]  
Brindley DA, 2012, REGEN MED, V7, P7, DOI [10.2217/RME.11.112, 10.2217/rme.11.112]
[3]   Very high density of CHO cells in perfusion by ATF or TFF in WAVE bioreactor. Part I. Effect of the cell density on the process [J].
Clincke, Marie-Francoise ;
Molleryd, Carin ;
Zhang, Ye ;
Lindskog, Eva ;
Walsh, Kieron ;
Chotteau, Veronique .
BIOTECHNOLOGY PROGRESS, 2013, 29 (03) :754-767
[4]   Concise Review: Guidance in Developing Commercializable Autologous/Patient-Specific Cell Therapy Manufacturing [J].
Eaker, Shannon ;
Armant, Myriam ;
Brandwein, Harvey ;
Burger, Scott ;
Campbell, Andrew ;
Carpenito, Carmine ;
Clarke, Dominic ;
Fong, Timothy ;
Karnieli, Ohad ;
Niss, Knut ;
Van't Hof, Wouter ;
Wagey, Ravenska .
STEM CELLS TRANSLATIONAL MEDICINE, 2013, 2 (11) :871-883
[5]   Microcarrier Culture for Efficient Expansion and Osteogenic Differentiation of Human Fetal Mesenchymal Stem Cells [J].
Goh, Tony Kwang-Poh ;
Zhang, Zhi-Yong ;
Chen, Allen Kuan-Liang ;
Reuveny, Shaul ;
Choolani, Mahesh ;
Chan, Jerry Kok Yen ;
Oh, Steve Kah-Weng .
BIORESEARCH OPEN ACCESS, 2013, 2 (02) :84-97
[6]  
Jones S. D., 2012, BIOPROCESS INT S, P4
[7]  
Ko HF, 2012, BIOPHARM INT, V25, P34
[8]   Statistical experimental design for bioprocess modeling and optimization analysis [J].
Lee, Kwang-Min ;
Gilmore, David F. .
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY, 2006, 135 (02) :101-115
[9]  
Leung HW, 2011, TISSUE ENG PART C-ME, V17, P165, DOI 10.1089/ten.TEC.2010.0320
[10]   Bioprocess Optimization Using Design-of-Experiments Methodology [J].
Mandenius, Carl-Fredrik ;
Brundin, Anders .
BIOTECHNOLOGY PROGRESS, 2008, 24 (06) :1191-1203